Decision catalogueModality pressure-test
Developability and crowding still break early antibody theses
Decision problem
Does target biology plus format novelty survive developability and competitor read-through before the raise?
Thesis
Differentiation that exists only in the deck — without nonclinical edge or a developability path — is not a decision-ready claim.
Antibody packages often overweight target popularity and underweight epitope rationale, failed analogues, and developability. Crowded targets need a sharper claim map: what has to be true for this binder or format to matter clinically and commercially.
Humanization, aggregation, viscosity, immunogenicity, and supply assumptions become financing-material when the raise funds a clinical path that assumes them solved. Bispecifics and ADCs add linker-payload or engager complexity that belongs on the claim map, not in an appendix.
The review also tests whether the clinical plan is powered relative to the commercial claim. Strong narrative language with a thin plan is a decision trigger.
Claim map
Must-be-true cuts a Decision Sprint memo would force
- Target and epitope rationale are supported beyond deck-level biology
- Differentiation holds against nearer-in competitors and failed analogues
- Developability, immunogenicity, and supply assumptions are financing-material and owned
Decision triggers
Outputs from the claim test that should change the conversation
- Crowded target with weak nonclinical differentiation
- Humanization or manufacturability risks deferred past the raise
- Clinical plan underpowered relative to the commercial claim
Sources
Related in the catalogue
- Prior work · Monoclonal antibodies
Anonymized account of decision pressure in this modality class.
- Method · graph-backed claim testing
How claims are decomposed, tested against the evidence graph, and turned into decision outputs.
- Claim maps beat generic diligence checklists for seed decisions
How should a lean team pressure-test science under a 5–20 day deal deadline?
- Platform story, asset check: separate them before you commit
Is this raise underwriting a product path or an unresolved platform science project?
Facing this cut on a live $1–10M package?
Scope a Decision Sprint for one opportunity under your deal deadline—claim map, risk register, management questions, and partner briefing.